210110-90-0
210110-90-0
Chemical Structure
Miglustat hydrochloride
Synonym(s): N-Butyldeoxynojirimycin hydrochloride; NB-DNJ hydrochloride; OGT 918 hydrochloride
- CAS No.: 210110-90-0
- Formula:C10H22ClNO4
- Molecular Weight:255.74
IUPAC Name: (2R,3R,4R,5S)-1-butyl-2-(hydroxymethyl)piperidine-3,4,5-triol hydrochloride
InChIKey: QPAFAUYWVZMWPR-ZSOUGHPYSA-N
SMILES: O[C@H]1[C@H](O)[C@@H](CO)N(CCCC)C[C@@H]1O.[H]Cl
Biological Activity: Miglustat (N-Butyldeoxynojirimycin) hydrochloride is an orally active and reversible ceramide glucosyltransferase inhibitor, with blood-brain barrier permeability. Miglustat hydrochloride can be used for the research of type I gaucher disease[1][2][3].
| Cat. No. | Product Name | Purity | Description | Pricing | |||||||||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
|
|
Miglustat hydrochloride | 99.97% | Miglustat (N-Butyldeoxynojirimycin) hydrochloride is an orally active and reversible ceramide glucosyltransferase inhibitor, with blood-brain barrier permeability. Miglustat hydrochloride can be used for the research of type I gaucher disease. | ||||||||||||||||||||
|
loading...
/
|
|||||||||||||||||||||||
|
|
Miglustat hydrochloride (Standard) | ≥98% | Miglustat (hydrochloride) (Standard) is the analytical standard of Miglustat (hydrochloride). This product is intended for research and analytical applications. Miglustat (N-Butyldeoxynojirimycin) hydrochloride is an orally active and reversible ceramide glucosyltransferase inhibitor. Miglustat hydrochloride can be used for the research of type I gaucher disease. | ||||||||||||||||||||
|
loading...
/
|
|||||||||||||||||||||||
|
|
Miglustat-d9 hydrochloride | 99.4% | Miglustat-d9 hydrochloride is the deuterium labeled Miglustat hydrochloride. Miglustat hydrochloride is an inhibitor of glucosylceramide synthase, primarily to treat Type I Gaucher disease (GD1). | ||||||||||||||||||||
|
loading...
/
|
|||||||||||||||||||||||
References
- [1]. Maria Cristina Dechecchi, et al. Anti-inflammatory effect of miglustat in bronchial epithelial cells. J Cyst Fibros. 2008 Nov;7(6):555-65. [Content Brief]
- [2]. G D'Arcangelo, et al. Miglustat Reverts the Impairment of Synaptic Plasticity in a Mouse Model of NPC Disease. Neural Plast. 2016:2016:3830424. [Content Brief]
- [3]. Patterson MC, et al. Miglustat for treatment of Niemann-Pick C disease: a randomised controlled study. Lancet Neurol. 2007 Sep;6(9):765-72. [Content Brief]
